Development of digital satiorx, a very low cost remotely controllable disposable microneedle transdermal drug delivery device able to deliver any liquid FDA approved transdermal drug
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91023C00059
- Awardee
-
Satio Inc. UEI H8WFVFLRQYN3
- Awarding agency
-
National Institutes of Health
Department of Health and Human Services
- Obligated
- $3,500,000
Award facts
- Opportunity
-
- A Solicitation of the Advanced Research Projects Agency for Health (ARPA-H) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · 75N91023R00041 · Posted May 17, 2023
- Contract value 100% obligated
- $3,500,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Boston, MA 02210, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Transfer Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,500,000 |
About this award
The Advanced Research Projects Agency for Health (ARPA-H) awarded a $3.5 million firm fixed-price definitive contract to Satio Inc., a small business concern, on September 30, 2023, for the development of Digital SatioRx, a low-cost, remotely controllable disposable microneedle transdermal drug delivery device capable of administering any FDA-approved transdermal liquid medication. The contract, set aside for small businesses with no more than 500 employees, is funded by the National Institutes of Health and has a completion deadline of February 3, 2026. Work will be performed in Boston, Massachusetts.
This award emerged from ARPA-H's Microneedle Transdermal Drug Delivery Device Topic 02 under the Small Business Innovation Research (SBIR) program solicitation 75N91023R00041, which sought innovative research proposals from small businesses to advance the agency's mission and promote technological innovation and commercialization. The original solicitation, posted in May 2023 with a July 2023 deadline, identified microneedle-based drug delivery patches as a key research area aligned with ARPA-H's broader objectives of scaling disruptive healthcare technologies from proof-of-concept to commercial deployment.
Quick answers
Who was awarded contract 75N91023C00059?
75N91023C00059 was awarded to Satio Inc. by National Institutes of Health (Department of Health and Human Services) on September 30, 2023.
How much is contract 75N91023C00059 worth?
The government has obligated $3,500,000 on 75N91023C00059.
Was contract 75N91023C00059 competed?
The extent of competition for 75N91023C00059 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award